IN8bio reports FY2022 net loss $28.5M; cash $18.2M; clinical data positive

IN8BIO, INC.

Cash $18.2M at Dec 31, 2022, down from $37.0M a year earlier; R&D spend $14.1M (FY2022) vs $7.3M.
Net loss $28.5M ($1.36/share) for FY2022 vs $14.7M ($1.47/share) in FY2021; Q4 loss $7.8M ($0.32/share).
INB-100 leukemia patients maintain durable complete responses beyond 18 months, up to 2.7 years in Phase 1.
INB-200 GBM trial: two patients progression-free at 1.5 and 1.2 years; enrolling Cohort 3; updated data mid-2023.
FDA cleared IND for INB-400 Phase 2 trial in GBM; enrollment expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IN8BIO, INC. reported financial results for the fourth quarter and full-year ended December 31, 2022.

Period: the fourth quarter and full-year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 30, 2023, IN8bio, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-010956

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.